摘要
Abstract
Objective:To investigate the clinical efficacy of Montelukast Sodium and Budesonide in the treatment of wheezy bronchopneumonia.Method:A total of 90 children with wheezing bronchopneumonia admitted to Qianxinan Traditional Chinese Medicine Hospital from April 2021 to June 2023 were selected,according to the random number table method,90 children were divided into two groups with 45 cases each.The control group was treated with Budesonide and the observation group was treated with Montelukast Sodium combined with Budesonide,both for 14 d.The clinical efficacy,time of symptom disappearance,serum inflammatory factors,blood routine and adverse effects were compared in two groups.Result:The clinical efficacy of the observation group was 95.56%(43/45),which was higher than 80.00%(36/45)of the control group,the difference was statistically significant(P<0.05).In the observation group,the fever time was(2.03±0.42)d,cough time was(4.25±1.36)d,wheezing sound disappeared time was(2.25±1.13)d,wet rales disappeared time was(4.81±1.27)d,wheezing disappeared time was(3.84±0.92)d,which were earlier than(3.05±0.52),(6.31±1.62),(5.61±1.72),(7.89±2.59),(6.22±1.26)d in the control group(P<0.05).After treatment,in the observation group,the hypersensitive C reactive protein(hs-CRP)was(6.42±0.85)mg/L,the white blood cell count(WBC)was(6.75±2.24)×109/L,and the percentage of neutrophils(NE%)was(46.12±3.29)%,which were lower than(7.04±0.92)mg/L,(10.62±2.51)×109/L,(54.58±3.87)%of the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Montelukast Sodium and Budesonide has obvious effect in treating children with wheezy bronchopneumonia,which can effectively promote the improvement of symptoms,reduce the level of serum inflammatory factors,and is safe and reliable.关键词
喘息性支气管肺炎/孟鲁司特钠/布地奈德/血常规Key words
Wheezy bronchopneumonia/Montelukast Sodium/Budesonide/Blood routine
